Mylan Announces Tentative Approval for Rabeprazole Sodium Delayed-Release Tablets
Posted on: Thursday, 19 January 2006, 15:00 CST
PITTSBURGH, Jan. 19 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Rabeprazole Sodium Delayed-release Tablets, 20 mg. Rabeprazole Sodium Delayed-release Tablets are the generic version of Eisai Medical Research Inc.'s Aciphex(R) Tablets, which had annual U.S. sales of approximately $1.3 billion as of June 2005.
Mylan Laboratories Inc. is a leading pharmaceutical company with three principal subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc. and UDL Laboratories, Inc. that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.
For more information about Mylan, visit http://www.mylan.com/.
First Call Analyst: FCMN Contact: patrick.fitzgerald@mylanlabs.com
Mylan Laboratories Inc.
CONTACT: Patrick Fitzgerald or Kris King of Mylan Laboratories Inc.,+1-724-514-1800
Web site: http://www.mylan.com/
Source: PRNewswire-FirstCall
Related Articles
- Mylan Laboratories: Acquisition Creates a Top-Three Generic Player
- Schaeffer's Upon Further Review Highlights the Following Stocks: Amazon.Com, Google, eBay, Travelzoo, and Mylan Laboratories
- Mylan Laboratories Appoints Carolyn Myers, Ph.D., President of Mylan Technologies Inc.
- Mylan Laboratories and Forest Laboratories Announce Nebivolol Licensing Agreement
- Mylan Announces Final Approval for Bisoprolol Fumarate Tablets, USP
- Mylan Announces Final FDA Approval for Glimepiride Tablets
- Mylan Laboratories Inc. Reports Positive Development From FDA Advisory Committee Vote on EMSAM(R)
- Mylan Laboratories Inc. Announces Executive Appointments
- Drugmaker Mylan Laboratories Reports Decline in Earnings, Revenue
- Mylan Receives Approval for Mercaptopurine Tablets USP, 50 Mg
 |
 |
User Comments (0)
RSS Feeds